1. Home
  2. HIVE vs FBRX Comparison

HIVE vs FBRX Comparison

Compare HIVE & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HIVE

HIVE Digital Technologies Ltd.

N/A

Current Price

$2.96

Market Cap

1.1B

Sector

N/A

ML Signal

N/A

Logo Forte Biosciences Inc.

FBRX

Forte Biosciences Inc.

N/A

Current Price

$76.93

Market Cap

899.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HIVE
FBRX
Founded
1987
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
899.4M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
HIVE
FBRX
Price
$2.96
$76.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
3
Target Price
$6.44
$67.00
AVG Volume (30 Days)
23.0M
2.3M
Earning Date
02-17-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.30
EPS
N/A
N/A
Revenue
$297,791,000.00
$36,000.00
Revenue This Year
$169.51
N/A
Revenue Next Year
$39.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
158.32
N/A
52 Week Low
$1.73
$10.18
52 Week High
$7.84
$77.20

Technical Indicators

Market Signals
Indicator
HIVE
FBRX
Relative Strength Index (RSI) 49.86 84.38
Support Level $2.63 $26.85
Resistance Level $3.40 $77.20
Average True Range (ATR) 0.23 0.08
MACD 0.06 -1.79
Stochastic Oscillator 53.90 98.72

Price Performance

Historical Comparison
HIVE
FBRX

About HIVE HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd is a sustainable-energy-focused digital infrastructure company that provides infrastructure solutions through the operation of Tier-1 and Tier-3 data centers. Its computing power is used for high-performance computing (HPC) and for generating hashrate sold to mining pools for cryptocurrency mining. The Company uses cash flow from its hashrate services business to support the expansion of its AI and HPC operations through its subsidiary. The Company focuses on Canada, Sweden, and Paraguay, where low-cost renewable power supports its operations and expansion. It operates in one segment with two revenue streams: the mining and sale of digital currencies and high-performance computing hosting. The majority of its revenue is generated from Bermuda.

About FBRX Forte Biosciences Inc.

Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

Share on Social Networks: